Education
About Us
Working with TipRanks
Follow Us
Medicenna Therapeutics Corp (MDNAF)
OTHER OTC:MDNAF
RESEARCH TOOLSreports
See the Price Targets and Ratings of:
MDNAF Financial Forecast
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$2.5
Buy
262.32%
Upside
Reiterated
12/06/24
H.C. Wainwright reiterates Buy Rating on Medicenna Therapeutics (MDNA)H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $2.50 price target on Medicenna Therapeutics (NASDAQ: MDNA).
JonesTrading
$3.48
Buy
403.90%
Upside
Reiterated
12/05/24
We believe the futility hurdle in r/r anal cancer is ORR of >20%. Prior clinical trials evaluating CPIs in anal cancer have shown ORR of 10-14% [S.Rao, J.-P.Spano, et al. ESMO Open. 2022, Vol. 7(4); A. Marabelle, J.-P. Delord, et al. Lancet, 2022, Vol. 7(5); S. Lonardi, F. Pietrantonio, et al. J Immunother Cancer. 2021, Vol. 9(11)].
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$2.5
Buy
262.32%
Upside
Reiterated
12/06/24
H.C. Wainwright reiterates Buy Rating on Medicenna Therapeutics (MDNA)H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $2.50 price target on Medicenna Therapeutics (NASDAQ: MDNA).
JonesTrading
$3.48
Buy
403.90%
Upside
Reiterated
12/05/24
We believe the futility hurdle in r/r anal cancer is ORR of >20%. Prior clinical trials evaluating CPIs in anal cancer have shown ORR of 10-14% [S.Rao, J.-P.Spano, et al. ESMO Open. 2022, Vol. 7(4); A. Marabelle, J.-P. Delord, et al. Lancet, 2022, Vol. 7(5); S. Lonardi, F. Pietrantonio, et al. J Immunother Cancer. 2021, Vol. 9(11)].
MDNAF Analyst Recommendation Trends
Rating
Feb 24
Apr 24
Aug 24
Nov 24
Dec 24
Strong Buy
4
5
3
3
3
Buy
0
1
2
2
2
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
4
6
5
5
5
Each month's total comprises the sum of three months' worth of ratings.
MDNAF Stock Forecast FAQ
What is MDNAF’s average 12-month price target, according to analysts?
Based on analyst ratings, Medicenna Therapeutics Corp’s 12-month average price target is $2.50.
What is MDNAF’s upside potential, based on the analysts’ average price target?
Medicenna Therapeutics Corp has 262.66% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MDNAF a Buy, Sell or Hold?
Medicenna Therapeutics Corp has a consensus rating of Moderate Buy which is based on 0 buy ratings, 0 hold ratings and 0 sell ratings.
What is Medicenna Therapeutics Corp’s price target?
The average price target for Medicenna Therapeutics Corp is $2.50. This is based on 0 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $2.50 ,the lowest forecast is $2.50. The average price target represents 262.66% Increase from the current price of $0.69.
The highest analyst price target is $2.50 ,the lowest forecast is $2.50. The average price target represents 262.66% Increase from the current price of $0.69.
What do analysts say about Medicenna Therapeutics Corp?
Medicenna Therapeutics Corp’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 0 Wall Streets Analysts.
How can I buy shares of MDNAF?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.